For several decades, it has been known that oestrogens are essential for human health. The discovery that there are two oestrogen receptors (ERs), ERalpha and ERbeta, has facilitated our understanding of how the hormone exerts its physiological effects. The ERs belong to the family of ligand-activated nuclear receptors, which act by modulating the expression of target genes. Studies of ER-knockout (ERKO) mice have been instrumental in defining the relevance of a given receptor subtype in a certain tissue. Phenotypes displayed by ERKO mice suggest diseases in which dysfunctional ERs might be involved in aetiology and pathology. Association between single-nucleotide polymorphisms (SNPs) in ER genes and disease have been demonstrated in several cases. Selective ER modulators (SERMs), which are selective with regard to their effects in a certain cell type, already exist. Since oestrogen has effects in many tissues, the goal with a SERM is to provide beneficial effects in one target tissue while avoiding side effects in others. Refined SERMs will, in the future, provide improved therapeutic strategies for existing and novel indications.
Skip Nav Destination
Review Article| June 01 2004
Nuclear receptors in disease: the oestrogen receptors
Maria Nilsson ;
Karin Dahlman-Wright ;
Essays Biochem (2004) 40: 157–167.
- Views Icon Views
- Share Icon Share
Iain J. McEwan, Maria Nilsson, Karin Dahlman-Wright, Jan-Åke Gustafsson; Nuclear receptors in disease: the oestrogen receptors. Essays Biochem 1 June 2004; 40 157–167. doi: https://doi.org/10.1042/bse0400157
Download citation file:
Don't already have an account? Register
Get Access To This Article
Buy This Article